Advertisement
Screener

INNOVIVA, INC. (INVA) Net Income (Loss) Available to Common Stockholders, Basic

2.8 / 5 stars · 68/120 Roast Me

INNOVIVA, INC. Net Income (Loss) Available to Common Stockholders, Basic

INNOVIVA, INC. (INVA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$83.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-05

  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$83.42M, a 230.98% decline year-over-year.
  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $186.59M.
  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $164.15M, a 707.36% increase year-over-year.
  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $89.91M, a 7312.04% increase year-over-year.
  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was $271.17M, a 1059.22% increase from fiscal 2024.
  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was $23.39M, a 86.98% decline from fiscal 2023.
  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was $179.72M, a 15.99% decline from fiscal 2022.
  • INNOVIVA, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $213.92M, a 19.53% decline from fiscal 2021.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 6 monthNet Income (Loss) Available to Common Stockholders, Basic 9 monthNet Income (Loss) Available to Common Stockholders, Basic 12 month
2026-06-30-$83.42M
10-Q · filed 2026-08-05
$103.17M
10-Q · filed 2026-08-05
$267.33M
derived: sum of 3 quarters · filed 2026-08-05
$357.24M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$186.59M
10-Q · filed 2026-05-06
$350.75M
derived: sum of 2 quarters · filed 2026-05-06
$440.66M
derived: sum of 3 quarters · filed 2026-05-06
$504.34M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$164.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$254.06M
derived: sum of 2 quarters · filed 2026-02-25
$317.75M
derived: sum of 3 quarters · filed 2026-08-05
$271.17M
10-K · filed 2026-02-25
2025-09-30$89.91M
10-Q · filed 2025-11-05
$153.60M
derived: sum of 2 quarters · filed 2026-08-05
$107.01M
10-Q · filed 2025-11-05
$127.34M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$63.69M
10-Q · filed 2026-08-05
$17.10M
10-Q · filed 2026-08-05
$37.44M
derived: sum of 3 quarters · filed 2026-08-05
$38.65M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$46.58M
10-Q · filed 2026-05-06
-$26.25M
derived: sum of 2 quarters · filed 2026-05-06
-$25.04M
derived: sum of 3 quarters · filed 2026-05-06
-$59.72M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$20.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$21.55M
derived: sum of 2 quarters · filed 2026-02-25
-$13.14M
derived: sum of 3 quarters · filed 2026-02-25
$23.39M
10-K · filed 2026-02-25
2024-09-30$1.21M
10-Q · filed 2025-11-05
-$33.47M
derived: sum of 2 quarters · filed 2025-11-05
$3.06M
10-Q · filed 2025-11-05
$64.59M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30-$34.69M
10-Q · filed 2025-08-06
$1.85M
10-Q · filed 2025-08-06
$63.38M
derived: sum of 3 quarters · filed 2026-02-25
$145.42M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$36.53M
10-Q · filed 2025-05-07
$98.06M
derived: sum of 2 quarters · filed 2026-02-25
$180.11M
derived: sum of 3 quarters · filed 2026-02-25
$181.39M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$61.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$143.58M
derived: sum of 2 quarters · filed 2026-02-25
$144.86M
derived: sum of 3 quarters · filed 2026-02-25
$179.72M
10-K · filed 2026-02-25
2023-09-30$82.05M
10-Q · filed 2024-11-06
$83.33M
derived: sum of 2 quarters · filed 2024-11-06
$118.19M
10-Q · filed 2024-11-06
$49.88M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$1.28M
10-Q · filed 2024-07-31
$36.15M
10-Q · filed 2024-07-31
-$32.17M
derived: sum of 3 quarters · filed 2025-02-26
$233.35M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$34.87M
10-Q · filed 2024-05-08
-$33.45M
derived: sum of 2 quarters · filed 2025-02-26
$232.07M
derived: sum of 3 quarters · filed 2025-02-26
$233.01M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31-$68.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$197.21M
derived: sum of 2 quarters · filed 2025-02-26
$198.15M
derived: sum of 3 quarters · filed 2025-02-26
$213.92M
10-K · filed 2025-02-26
2022-09-30$265.52M
10-Q · filed 2023-11-01
$266.46M
derived: sum of 2 quarters · filed 2023-11-01
$282.24M
10-Q · filed 2023-11-01
$292.58M
derived: sum of 4 quarters · filed 2024-03-05
2022-06-30$939.00K
10-Q · filed 2023-08-02
$16.71M
10-Q · filed 2023-08-02
$27.06M
derived: sum of 3 quarters · filed 2024-03-05
$99.50M
derived: sum of 4 quarters · filed 2024-03-05
2022-03-31$15.77M
10-Q · filed 2023-05-09
$26.12M
derived: sum of 2 quarters · filed 2024-03-05
$98.56M
derived: sum of 3 quarters · filed 2024-03-05
$187.50M
derived: sum of 4 quarters · filed 2024-03-05
2021-12-31$10.35M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05
$82.78M
derived: sum of 2 quarters · filed 2024-03-05
$171.73M
derived: sum of 3 quarters · filed 2024-03-05
$265.85M
10-K/A · filed 2024-03-05
2021-09-30$72.44M
10-Q · filed 2022-11-09
$161.39M
derived: sum of 2 quarters · filed 2022-11-09
$255.51M
10-Q · filed 2022-11-09
$309.41M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$88.95M
10-Q · filed 2022-07-27
$183.07M
10-Q · filed 2022-07-27
$236.97M
derived: sum of 3 quarters · filed 2023-02-28
$265.19M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$94.12M
10-Q · filed 2022-05-05
$148.03M
derived: sum of 2 quarters · filed 2023-02-28
$176.24M
derived: sum of 3 quarters · filed 2023-02-28
$253.09M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$53.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$82.12M
derived: sum of 2 quarters · filed 2023-02-28
$158.97M
derived: sum of 3 quarters · filed 2023-02-28
$224.40M
10-K · filed 2023-02-28
2020-09-30$28.22M
10-Q · filed 2021-10-27
$105.06M
derived: sum of 2 quarters · filed 2021-10-27
$170.50M
10-Q · filed 2021-10-27
$216.45M
derived: sum of 4 quarters · filed 2021-10-27
2020-06-30$76.84M
10-Q · filed 2021-07-29
$142.28M
10-Q · filed 2021-07-29
$188.23M
derived: sum of 3 quarters · filed 2021-07-29
$228.04M
derived: sum of 4 quarters · filed 2021-07-29
2020-03-31$65.44M
10-Q · filed 2021-04-28
$111.39M
derived: sum of 2 quarters · filed 2021-04-28
$151.19M
derived: sum of 3 quarters · filed 2021-04-28
$188.94M
derived: sum of 4 quarters · filed 2021-04-28
2019-12-31$45.95M
10-K · filed 2020-02-19
$85.76M
derived: sum of 2 quarters · filed 2020-10-28
$123.50M
derived: sum of 3 quarters · filed 2020-10-28
$157.29M
10-K/A · filed 2022-03-17
2019-09-30$39.81M
10-Q · filed 2020-10-28
$77.55M
derived: sum of 2 quarters · filed 2020-10-28
$111.34M
10-Q · filed 2020-10-28
$375.10M
derived: sum of 4 quarters · filed 2020-10-28
2019-06-30$37.74M
10-Q · filed 2020-07-29
$71.53M
10-Q · filed 2020-07-29
$335.29M
derived: sum of 3 quarters · filed 2020-07-29
$382.38M
derived: sum of 4 quarters · filed 2020-07-29
2019-03-31$33.79M
10-Q · filed 2020-04-29
$297.55M
derived: sum of 2 quarters · filed 2020-04-29
$344.64M
derived: sum of 3 quarters · filed 2020-04-29
$399.26M
derived: sum of 4 quarters · filed 2020-04-29
2018-12-31$263.76M
10-K · filed 2020-02-19
$310.85M
derived: sum of 2 quarters · filed 2020-02-19
$365.48M
derived: sum of 3 quarters · filed 2020-02-19
$395.06M
10-K · filed 2021-02-25
2018-09-30$47.09M
10-K · filed 2020-02-19
$101.72M
derived: sum of 2 quarters · filed 2020-02-19
$131.30M
10-Q · filed 2019-10-30
$189.68M
derived: sum of 4 quarters · filed 2020-02-19
2018-06-30$54.63M
10-K · filed 2020-02-19
$84.21M
10-Q · filed 2019-07-24
$142.59M
derived: sum of 3 quarters · filed 2020-02-19
$166.36M
derived: sum of 4 quarters · filed 2020-02-19
2018-03-31$29.58M
10-K · filed 2020-02-19
$87.97M
derived: sum of 2 quarters · filed 2020-02-19
$111.73M
derived: sum of 3 quarters · filed 2020-02-19
$146.88M
derived: sum of 4 quarters · filed 2020-02-19
2017-12-31$58.38M
10-K · filed 2019-02-19
$82.15M
derived: sum of 2 quarters · filed 2019-02-19
$117.30M
derived: sum of 3 quarters · filed 2019-02-19
$134.14M
10-K · filed 2020-02-19
2017-09-30$23.77M
10-K · filed 2019-02-19
$58.91M
derived: sum of 2 quarters · filed 2019-02-19
$75.76M
10-Q · filed 2018-10-31
$101.64M
derived: sum of 4 quarters · filed 2019-02-19
2017-06-30$35.15M
10-K · filed 2019-02-19
$51.99M
10-Q · filed 2018-07-26
$77.87M
derived: sum of 3 quarters · filed 2019-02-19
$92.91M
derived: sum of 4 quarters · filed 2019-02-19
2017-03-31$16.84M
10-K · filed 2019-02-19
$42.73M
derived: sum of 2 quarters · filed 2019-02-19
$57.76M
derived: sum of 3 quarters · filed 2019-02-19
$72.36M
derived: sum of 4 quarters · filed 2019-02-19
2016-12-31$25.88M
10-K · filed 2017-02-28
$40.92M
derived: sum of 2 quarters · filed 2017-11-03
$55.51M
derived: sum of 3 quarters · filed 2017-11-03
$59.54M
10-K · filed 2019-02-19
2016-09-30$15.03M
10-Q · filed 2017-11-03
$29.63M
derived: sum of 2 quarters · filed 2017-11-03
$34.06M
10-Q · filed 2017-11-03
$38.37M
derived: sum of 4 quarters · filed 2017-11-03
2016-06-30$14.60M
10-Q · filed 2017-08-08
$19.03M
10-Q · filed 2017-08-08
$23.33M
derived: sum of 3 quarters · filed 2017-08-08
$18.75M
derived: sum of 4 quarters · filed 2017-08-08
2016-03-31$4.43M
10-Q · filed 2017-05-05
$8.74M
derived: sum of 2 quarters · filed 2017-05-05
$4.15M
derived: sum of 3 quarters · filed 2017-05-05
-$3.66M
derived: sum of 4 quarters · filed 2017-05-05
2015-12-31$4.30M
10-K · filed 2017-02-28
-$283.00K
derived: sum of 2 quarters · filed 2017-02-28
-$8.09M
derived: sum of 3 quarters · filed 2017-02-28
-$18.76M
10-K · filed 2018-02-23
2015-09-30-$4.58M
10-K · filed 2017-02-28
-$12.39M
derived: sum of 2 quarters · filed 2017-02-28
-$23.06M
10-Q · filed 2016-11-03
-$38.99M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30-$7.81M
10-K · filed 2017-02-28
-$18.48M
10-Q · filed 2016-08-04
-$34.40M
derived: sum of 3 quarters · filed 2017-02-28
-$55.67M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31-$10.67M
10-K · filed 2017-02-28
-$26.59M
derived: sum of 2 quarters · filed 2017-02-28
-$47.86M
derived: sum of 3 quarters · filed 2017-02-28
-$111.43M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31-$15.93M
10-K · filed 2016-02-24
-$37.20M
derived: sum of 2 quarters · filed 2016-02-24
-$100.76M
derived: sum of 3 quarters · filed 2016-02-24
-$168.46M
10-K · filed 2017-02-28
2014-09-30-$21.27M
10-K · filed 2016-02-24
-$84.83M
derived: sum of 2 quarters · filed 2016-02-24
-$152.54M
10-Q · filed 2015-11-05
-$202.47M
derived: sum of 4 quarters · filed 2016-02-24
2014-06-30-$63.56M
10-K · filed 2016-02-24
-$131.27M
10-Q · filed 2015-08-06
-$181.20M
derived: sum of 3 quarters · filed 2016-02-24
-$228.18M
derived: sum of 4 quarters · filed 2016-02-24
2014-03-31-$67.70M
10-K · filed 2016-02-24
-$117.63M
derived: sum of 2 quarters · filed 2016-02-24
-$164.62M
derived: sum of 3 quarters · filed 2016-02-24
-$201.05M
derived: sum of 4 quarters · filed 2016-02-24
2013-12-31-$49.93M
10-K · filed 2015-02-27
-$96.91M
derived: sum of 2 quarters · filed 2015-02-27
-$133.34M
derived: sum of 3 quarters · filed 2015-02-27
-$170.70M
10-K · filed 2016-02-24
2013-09-30-$46.98M
10-K · filed 2015-02-27
-$83.41M
derived: sum of 2 quarters · filed 2015-02-27
-$120.77M
10-Q · filed 2014-11-04
-$152.10M
derived: sum of 4 quarters · filed 2015-02-27
2013-06-30-$36.43M
10-K · filed 2015-02-27
-$73.79M
10-Q · filed 2014-08-07
-$105.11M
derived: sum of 3 quarters · filed 2015-02-27
-$139.81M
derived: sum of 4 quarters · filed 2015-02-27
2013-03-31-$37.36M
10-K · filed 2015-02-27
-$68.68M
derived: sum of 2 quarters · filed 2015-02-27
-$103.38M
derived: sum of 3 quarters · filed 2015-02-27
-$140.50M
derived: sum of 4 quarters · filed 2015-02-27
2012-12-31-$31.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27
-$66.02M
derived: sum of 2 quarters · filed 2015-02-27
-$103.14M
derived: sum of 3 quarters · filed 2015-02-27
-$18.54M
10-K · filed 2015-02-27
2012-09-30-$34.69M
10-Q · filed 2013-11-01
-$71.81M
derived: sum of 2 quarters · filed 2013-11-01
$12.78M
10-Q · filed 2013-11-01
-$24.23M
derived: sum of 4 quarters · filed 2014-03-03
2012-06-30-$37.12M
10-Q · filed 2013-08-01
$47.47M
10-Q · filed 2013-08-01
$10.47M
derived: sum of 3 quarters · filed 2014-03-03
-$20.16M
derived: sum of 4 quarters · filed 2014-03-03
2012-03-31$84.59M
10-Q · filed 2013-05-01
$47.59M
derived: sum of 2 quarters · filed 2014-03-03
$16.96M
derived: sum of 3 quarters · filed 2014-03-03
-$8.08M
derived: sum of 4 quarters · filed 2014-03-03
2011-12-31-$37.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03
-$67.63M
derived: sum of 2 quarters · filed 2014-03-03
-$92.68M
derived: sum of 3 quarters · filed 2014-03-03
-$115.34M
10-K · filed 2014-03-03
2011-09-30-$30.63M
10-Q · filed 2012-10-31
-$55.67M
derived: sum of 2 quarters · filed 2012-10-31
-$78.34M
10-Q · filed 2012-10-31
2011-06-30-$25.05M
10-Q · filed 2012-08-01
-$47.71M
10-Q · filed 2012-08-01
2010-12-31-$19.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26
-$40.52M
derived: sum of 2 quarters · filed 2013-02-26
-$83.86M
10-K · filed 2013-02-26
2010-09-30-$21.22M
10-Q · filed 2011-11-02
-$64.56M
10-Q · filed 2011-11-02
2009-12-31-$85.30M
10-K · filed 2012-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10